{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:11:03Z","timestamp":1785499863135,"version":"3.56.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Preterm birth (PTB) is the leading cause of infant morbidity and mortality worldwide. It has been suggested that vaginal progesterone (VP) treatment may reduce the recurrence of PTB.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the association of VP treatment with prevention of recurrent PTB among patients with a singleton pregnancy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective, observational cohort study, set in a public health care system for inner-city pregnant patients, enrolled patients with prior spontaneous PTB (gestational age, \u226435 weeks) receiving VP from May 15, 2017, to May 7, 2019. Patients who delivered between 1998 and 2011 served as a referent cohort matched 3:1 for obesity, race and ethnicity, and individual specific preterm birth history. Statistical analysis was performed from August 19, 2021, to September 2, 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Patients received 90 mg of vaginal progesterone, 8%, nightly, initiated between 16 weeks and 0 days and 20 weeks and 6 days of pregnancy until 36 weeks and 6 days of pregnancy or delivery.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was overall rate of recurrent PTB at 35 weeks or less of patients given VP compared with the 3:1 matched untreated historical controls. Secondary outcomes included assessment of PTB according to adherence (\u226580% completing scheduled doses), duration of pregnancy relative to index gestational age, progesterone blood levels, and outcomes for those who declined VP.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 417 patients (mean [SD] age, 30.4 [5.9] years; 64 Black patients [15.3%]; 272 [65.2%] with a body mass index of \u226530) received VP and were matched with 1251 controls (mean [SD] age, 28.8 [5.7] years; 192 Black patients [15.3%]; 816 [65.2%] with a body mass index of \u226530). The overall rate of recurrent PTB was 24.0% (100 of 417; 95% CI, 20.0%-28.4%) for the VP cohort compared with 16.8% (1394 of 8278) expected in the matched historical controls. Adherence was not associated with lower rates of recurrent PTB compared with nonadherence (odds ratio, 0.87 [95% CI, 0.51-1.41]). The mean difference between historical matched controls and those using VP was 0.2 weeks (95% CI, \u22121.4 to 1.0 weeks) without improvement in the interval of recurrent PTB after the implementation of VP (P<\/jats:italic>\u2009=\u2009.73). Progesterone blood levels for patients who were adherent compared with those who were nonadherent were not significantly different at either 24 or 32 weeks (24 weeks: 99 ng\/mL [95% CI, 85-121 ng\/mL] vs 104 ng\/mL [95% CI, 89-125 ng\/mL]; P<\/jats:italic>\u2009=\u2009.16; 32 weeks: 200 ng\/mL [95% CI, 171-242 ng\/mL] vs 196 ng\/mL [95% CI, 155-271 ng\/mL]; P<\/jats:italic>\u2009=\u2009.69).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study of patients with a current singleton pregnancy suggests that VP was not associated with a reduction in recurrent PTB.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.37600","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T15:33:08Z","timestamp":1667230388000},"page":"e2237600","source":"Crossref","is-referenced-by-count":17,"title":["Association of Vaginal Progesterone Treatment With Prevention of Recurrent Preterm Birth"],"prefix":"10.1001","volume":"5","author":[{"given":"David B.","family":"Nelson","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas"},{"name":"Department of Obstetrics, Parkland Health, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlyn","family":"Lafferty","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmayee","family":"Venkatraman","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey G.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Center for Human Nutrition, University of Texas Southwestern Medical Center at Dallas, Dallas"},{"name":"Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn M.","family":"Eckert","sequence":"additional","affiliation":[{"name":"Center for Human Nutrition, University of Texas Southwestern Medical Center at Dallas, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald D.","family":"McIntire","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Y.","family":"Spong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"issue":"2","key":"zoi221065r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45808","article-title":"Seasonality associated with preterm birth\u2014are we borrowing from our children?","volume":"5","author":"Nelson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi221065r2","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2214-109X(18)30451-0","article-title":"Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis.","volume":"7","author":"Chawanpaiboon","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"6198","key":"zoi221065r3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1126\/science.1251816","article-title":"Preterm labor: one syndrome, many causes.","volume":"345","author":"Romero","year":"2014","journal-title":"Science"},{"issue":"6","key":"zoi221065r4","doi-asserted-by":"publisher","first-page":"576.e1","DOI":"10.1016\/j.ajog.2007.01.039","article-title":"Recurrence risk for preterm delivery.","volume":"196","author":"McManemy","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"zoi221065r5","first-page":"379","article-title":"Recurrence of preterm birth in singleton and twin pregnancies.","volume":"98","author":"Bloom","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"6","key":"zoi221065r6","doi-asserted-by":"publisher","first-page":"600.e1","DOI":"10.1016\/j.ajog.2017.02.025","article-title":"17-Alpha hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.","volume":"216","author":"Nelson","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"zoi221065r7","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1097\/AOG.0000000000004479","article-title":"Prediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234.","volume":"138","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Obstetrics","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"1","key":"zoi221065r8","doi-asserted-by":"publisher","first-page":"B16","DOI":"10.1016\/j.ajog.2020.04.001","article-title":"SMFM statement: use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth.","volume":"223","author":"Society for Maternal-Fetal Medicine (SMFM) Publications Committee","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"zoi221065r9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-0039-3400227","article-title":"17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study): a multicenter, international, randomized double-blind trial.","volume":"37","author":"Blackwell","year":"2020","journal-title":"Am J Perinatol"},{"issue":"3","key":"zoi221065r10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/AOG.0b013e318195e257","article-title":"Decreased preterm births in an inner-city public hospital.","volume":"113","author":"Leveno","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi221065r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2021.100442","article-title":"Geographic barriers to prenatal care access and their consequences.","volume":"3","author":"Holcomb","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"3","key":"zoi221065r12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ajog.2017.11.582","article-title":"Reply.","volume":"218","author":"Nelson","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"10033","key":"zoi221065r15","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(16)00350-0","article-title":"Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.","volume":"387","author":"Norman","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"zoi221065r16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ajog.2019.02.032","article-title":"Defining 17OHP-C responsiveness.","volume":"220","author":"Nelson","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"zoi221065r17","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1194\/jlr.D800017-JLR200","article-title":"Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS\/MS.","volume":"49","author":"Honda","year":"2008","journal-title":"J Lipid Res"},{"issue":"2","key":"zoi221065r18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ajog.2020.09.045","article-title":"A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.","volume":"224","author":"Nelson","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"10280","key":"zoi221065r19","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(21)00217-8","article-title":"Evaluating Progestogens for Preventing Preterm Birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.","volume":"397","author":"EPPPIC Group","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"zoi221065r20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ajog.2022.04.023","article-title":"Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? evidence from a systematic review and meta-analysis.","volume":"227","author":"Conde-Agudelo","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"zoi221065r21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes.","volume":"9","author":"Baumgartner","year":"2018","journal-title":"Front Pharmacol"},{"key":"zoi221065r22","doi-asserted-by":"publisher","journal-title":"Microbiome","DOI":"10.1186\/s40168-016-0223-9"},{"issue":"2","key":"zoi221065r23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ajog.2017.11.576","article-title":"Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data.","volume":"218","author":"Romero","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"zoi221065r13","unstructured":"US Food and Drug Administration. FDA briefing document: NDA 021945: hydroxyprogesterone caproate injection (trade name Makena). Accessed June 12, 2022. https:\/\/www.fda.gov\/media\/132003\/download"},{"key":"zoi221065r14","unstructured":"Sison? G. The Morisky Medication Adherence Scale: an overview. Accessed June 12, 2022. https:\/\/www.pillsy.com\/articles\/the-morisky-medication-adherence-scale-definition-alternatives-and-overview"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797988\/nelson_2022_oi_221065_1666636862.73959.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T15:33:12Z","timestamp":1667230392000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.37600","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}